Clinical Trials
13
Active:1
Completed:9
Trial Phases
4 Phases
Phase 1:6
Phase 2:2
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (46.2%)Phase 3
3 (23.1%)Not Applicable
2 (15.4%)Phase 2
2 (15.4%)Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT07181538
- Locations
- 🇰🇷
Yangji Hospital, Seoul, South Korea
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
Not Applicable
Not yet recruiting
- Conditions
- Non-erosive Gastroesophageal Reflux Disease
- Interventions
- Drug: JP-1366 + placeboDrug: Placebo + Placebo
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 321
- Registration Number
- NCT07160790
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
Phase 3
Recruiting
- Conditions
- Peptic Ulcer
- Interventions
- Drug: Lanston Capsule 15 mgDrug: JP-1366 10 mgDrug: Lanston Capsule 15 mg placeboDrug: JP-1366 10 mg placebo
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 364
- Registration Number
- NCT06439563
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JP-1366 20mg tabletDrug: JP-1366 20mg capsule
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05814809
- Locations
- 🇰🇷
Yangji Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JP-1366 20mg tablet
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05712681
- Locations
- 🇰🇷
Asan Medical Central, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
No news found